Menu

USFDA

Analysts Weigh In: KFin Technologies' Ascent Acquisition Could Drive Future Growth

Analysts Weigh In: KFin Technologies' Ascent Acquisition Could Drive Future Growth

Analysts Weigh In: KFin Technologies’ Ascent Acquisition Could Drive Future Growth

 

Analysts Are Upbeat About Long-Term Value Creation as KFin Technologies Soars on Ascent Acquisition

Stock Jumps 9% After Deal News

Shares of KFin Technologies Ltd. rallied nearly 9% on April 17, continuing their upward momentum for the third consecutive trading session. This surge comes on the heels of the company’s announcement regarding its acquisition of a controlling interest in Ascent Fund Services, a global fund administration firm headquartered in Singapore.
Despite the recent rally, KFin Tech’s stock remains around 30% below its all-time high of ₹1,641.35, which it had reached in December 2023. As of the latest trade, shares were up 8.66% at ₹1,143.50, although they remain down over 25% in 2025.

Details of the Acquisition

A formal deal has been reached for KFin Technologies to pay $34.7 million for a 51 percent share in Ascent Fund Services. The deal structure comprises a primary infusion of $5 million into Ascent and a secondary share purchase of $29.7 million, valuing the firm at an enterprise value of $63 million.
The remaining 49% stake is expected to be acquired over the period of 2028 to 2030, allowing KFin Tech to eventually gain full control of Ascent’s operations. The company aims to complete the initial leg of the deal within the next 3–4 months.

Expanding Global Reach

Ascent operates in 13 international markets and serves a client base of over 260 asset managers, with total assets under administration amounting to $24 billion. While there are some overlapping geographies between the two firms, Ascent adds new strategic territories such as the Cayman Islands, British Virgin Islands (BVI), the US, and the UK, thereby significantly expanding KFin Tech’s global footprint.
Analysts believe this move aligns with KFin Tech’s objective of becoming a global leader in fund administration and investor services, complementing its existing operations in India and through its subsidiary Hexagram.

Brokerages React Positively

Several global and domestic brokerages have reacted positively to the news, emphasizing the strategic merit and valuation attractiveness of the deal.
Jefferies highlighted that Ascent’s client relationships, experienced team, international licenses, and market presence will significantly bolster KFin Technologies’ international expansion plans. The brokerage noted that although Ascent currently operates at lower margins, KFin aims to align them with its own margin profile of around 45%, as seen in Q3 FY25.
Jefferies maintained a ‘Buy’ rating on the stock and set a price target of ₹1,310 per share, calling the deal attractively priced at 3.5x price-to-sales — notably lower than the 13x–17x P/S multiples seen for peers like CAMS and even KFin itself.

Nuvama Foresees Long-Term Gains

With a slightly reduced price objective of ₹1,230, Nuvama Institutional Equities has kept its “Buy” recommendation on the company. The firm acknowledged the deal may be earnings-dilutive in the short term due to Ascent’s thinner margins and ongoing integration costs. However, Nuvama expects the acquisition to be value-accretive in the long run, especially if KFin can retain Ascent’s promoters and key sales talent.

Nuvama’s assessment highlights that the acquisition of Ascent enhances KFin Tech’s ability to tap into significant client networks. However, realizing long-term benefits will depend on consistent leadership and retaining key team members. Working Together Strategically with Hexagram

Strategic Synergy with Hexagram

Another prominent brokerage, Motilal Oswal, termed the acquisition a strategic fit with KFin Tech’s existing global operations. With KFin already operating through Hexagram, the integration of Ascent is expected to complement its service offerings, enabling the company to serve a wider and more diversified clientele.
Motilal emphasized that this acquisition sets the stage for deeper international presence and product innovation.

Market Sentiment Split, But Tilts Positive

Out of 16 analysts covering KFin Technologies, nine have a ‘Buy’ rating, four recommend holding, and three maintain a ‘Sell’ call. This split highlights that while optimism is strong among some brokerages, others are exercising caution due to short-term earnings implications.
Still, the overall tone remains constructive, with many analysts agreeing that the Ascent deal is a bold step in KFin Tech’s global ambitions and a long-term value driver.

Final Thoughts: Strategic Deal Opens Global Doors Despite Short-Term Earnings Hit

The purchase of the majority of Ascent Fund Services by KFin Technologies represents a significant turning point in the business’s international expansion plan. While short-term margin pressures and integration risks remain, the long-term benefits — expanded client base, geographic diversification, and strategic synergies — offer promising upside.

The recent surge in share price indicates that investors are becoming more confident in KFin Tech’s mission. If the company executes the integration efficiently and retains critical leadership at Ascent, this deal could become a turning point in establishing KFin as a formidable global player in fund administration services.

 

 

 

 

 

 

 

 

 

The image added is for representation purposes only

CRISIL sees strong 12–13% credit growth ahead

Lupin Soars on USFDA Nod for Billion-Dollar Drug

Lupin ltd consolidated revenue fell by 14% YOY to Rs 3604 Cr.

In Q1FY23, Lupin ltd consolidated revenue fell by 14% YOY to Rs 3604 Cr.

Lupin limited is a multi-national pharmaceutical company based in Mumbai. The company specialises in branded and generic formulations, APIs and advanced drug delivery systems in biotechnology. It has 18 manufacturing sites and 9 R&D sites across the globe.

Lupin ltd consolidated revenue fell by 14.9% YOY to Rs 3604 Crores, in Q1FY23, due to subdued performance of its US business.EBITDA was down by 76% YOY to Rs 238 Crores. EBITDA margin falls by 1680 basis points.YOY to 6.6% due to raw martial inflation, higher employee spends and other expenses. Consequently , company reported a loss of Rs 89 Crores. As against of Rs 542 Crores profit a year ago. Company increasing market share, new product ,and scaling up of the Indian business indicate well for the company  performance.

Financial highlights :

In Q1FY23, lupin ltd consolidated revenue declined by 12.3% YOY and QOQ to Rs 3.74Crores.it is mainly due to muted performance in the US business. Revenue from the US business declined by 24.2% YOY and 28.7%Quarter On Quarter to Rs 1010 Crores due to inventory writw down , shelf stock adjustments and price erosion. Company s Indian revenue stood at Rs 1492 Crores which is down by 8.85 YOY and up by 10.4% QOQ DRIVEN BY A 9.9% Quarter on quarter driven by a 9.9 % QOQ growth in domestic formulations. API revenue grew by 3.7% YOY and 15.8% QOQ to Rs 255 Crores. While revenue from growth markets rose by 27.3% YOY and 11.2% QOQ to Rs 424 Crores.

Margins impacted due to raw material inflation:

Gross margin of company contracted by 720 basis points YOY to 55.3% as the company pared down inventories and took shelf shock adjustments on select products consequently; EBITDA fell by 76% YOY to Rs 238 Crores. Company owing to further price erosion in the US business and inflation in input materials. EBITDA margin thereby shrink  by  16.8% YOY to 6.4% reported a loss stood at Rs 89  Crores as against Rs 542 Crores .

Quarter highlights:  

Capex stood at Rs 161 Crores against Rs 106 Cr in Q1FY22 and Rs 158 Crores in Q4FY22. R&D expense was at Rs 348 Crores against Rs 374 Crores in Q1FY22 And Rs 344 Crores in Q4FY22. Total marketed generic products stood at 167. It launched cyclosporine ophthalmic in the US in the quarter. Current pipeline includes 54 FTF, OF Which 21 exclusive FTFs are awaiting for the USFDA approval. In India business, the company has a revenue run rate of more than Rs 1000 Crores. In cardiac and anti-diabetics .GI, pain and gynae grew in double digits.

Valuation:

The EPS was Rs. -1.96, compared to Rs. 10.15 in June 2021. The ROCE and ROE were at  -7.16% and -11.8%, respectively. The book value of a stock is Rs 267. The company’s asset turnover ratio was 0.73x. The scrip is trading at Rs.717, up by 5.40%. on Monday.

Astral Pipes posted a net profit of Rs. 96 Cr.

 

CSL Strategizes to Shield Lifesaving Therapies from Tariff Impacts

USFDA classify three Aurobindo units under Official Action Indicated (OAI)

Aurobindo Pharma Ltd experienced a decline in its share prices on 17th May 2019. The company reported to the exchanges about three of its plants classified as Official Action Indicated...
Wockhardt gets USFDA approval for cancer drug

Wockhardt gets USFDA approval for cancer drug

On April 10, 2019, the Biotechnology and Pharmaceutical major Wockhardt Ltd received US Food and Drug Administration (USFDA) approval for an ANDA of 50 mg injection of Decitabine injection. Decitabine...

Aurobindo Pharma acquires 7 oncology injectables from Spectrum Pharma

Aurobindo Pharma USA Inc’s wholly owned subsidiary Acrotech Biopharma LLC which in turn is a wholly own subsidiary of Aurobindo Pharma Limited. On 2nd March 2019 Aurobindo Pharma Limited’s subsidiary,...
USFDA issues form 483 to Dr. Reddy's Laboratories

USFDA issues form 483 to Dr. Reddy's Laboratories

Dr Reddy’s laboratories plunged nearly 29.77%. It hit an intra-day low of Rs. 1872.95 on 15th February 2019. The company also hit 52 weeks low today on NSE and BSE....
Indian Pharma Q4 Results: Domestic Demand and Specialty Generics Drive Robust Profitability Surge

Q2FY19 Results, Aurobindo Pharma Ltd. posted Rs 611.40 crores net profit

Aurobindo Pharma Limited is a fully integrated pharmaceutical company, incorporated in the year 1986. The Company manufactures Generic pharmaceutical, Active Pharmaceuticals Ingredients (API), Formulation drugs and speciality products. The companies...